Clinical Trial Update: Pembrolizumab + Poly-ICLC in MRP Colon Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating pembrolizumab in combination with Poly-ICLC for metastatic colon cancer has completed enrollment and posted results on 2024-06-07.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Poly-ICLC (poly-ICLC)

Snippet

Sponsor: Asha Nayak | Conditions: Metastatic Colon Cancer, Solid Tumor | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-06-07